# Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5

> **NCT07631208** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 24 (estimated)

## Conditions studied

- Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5

## Interventions

- **DRUG:** Teclistamab(SC)

## Key facts

- **NCT ID:** NCT07631208
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-30
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07631208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07631208, "Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07631208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*